1
|
Long L, Li Q. The effect of alkaloid from Oxytropis ochrocephala on growth inhibition and expression of PCNA and p53 in mice bearing H22 Hepatocellular Carcinoma. YAKUGAKU ZASSHI 2005; 125:665-70. [PMID: 16079618 DOI: 10.1248/yakushi.125.665] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
To study the antitumor activity of alkaloid extracted from Oxytropis ochrocephala and its possible mechanism, we observed the effect of alkaloid on tumor weight and expression of PCNA and p53 in mice bearing H(22) hepatocellular carcinoma by means of immunohistochemistry SP method. After treatment with alkaloid from Oxytropis ochrocephala, the results showed that alkaloid administration (25 and 50 mg/kg body weight, p.o.) could inhibit H(22) hepatocellular carcinoma growth to various extent, and the rates of inhibition were 48.5% and 57.7% respectively (p<0.01). The antitumor activity of the alkaloid is in a dose dependent manner, with no signs of toxicity to weight, kidney and liver. The sections of tumor showed the number of tumor cell decreased and nucleus appeared putrescence such as nucleus atrophy, disintegrating and dissolving. Meanwhile, the expression of PCNA and mutant p53 protein positive cell numbers in mice bearing H(22) hepatocellular carcinoma also suppressed by alkaloid (p<0.05). It suggested that Alkaloid from Oxytropis ochrocephala showed antitumor effect and its possible mechanism might be associated with the expression inhibition of PCNA and mutant p53 protein. Further studies are needed to explore the antitumor activity of the other compounds of Oxytropis ochrocephala and to specify their possible mechanism of action.
Collapse
Affiliation(s)
- Ling Long
- College of Animal Science, Northwest Agriculture and Forestry University, Shannxi Province, People's Republic of China
| | | |
Collapse
|
2
|
Ferraz A, Faria DH, Benneti MN, da Rocha AB, Schwartsmann G, Henriques A, von Poser GL. Screening for antiproliferative activity of six southern Brazilian species of Hypericum. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2005; 12:112-115. [PMID: 15693717 DOI: 10.1016/j.phymed.2003.07.015] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The crude methanolic extracts of six species of Hypericum growing in southern Brazil (Hypericum caprifoliatum Cham. & Schlecht., H. carinatum Griseb., H. connatum Lam., H. myrianthum Cham. & Schlecht., H. polyanthemum Klotzsch ex Reichardt and H. ternum A. St. Hil.) were screened for their antiproliferative activity against two cell lines (HT-29 human colon carcinoma cells and H-460 non-small cell lung carcinoma). The most active crude extracts were those from H. caprifoliatum, H. myrianthum and, to a lesser extent, from H. connatum. All plants were submitted to fractionation with solvents in increasing polarity and re-assayed for the two cell lines used previously, as well as U-373 human malignant glioma cells. The most active fractions were the hexane fractions obtained from H. caprifoliatum, H. myrianthum and H. ternum.
Collapse
Affiliation(s)
- A Ferraz
- Programa de Pós Graduação em Ciências Farmacêuticas, UFRGS, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brazil
| | | | | | | | | | | | | |
Collapse
|
3
|
Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol 2001; 2:221-5. [PMID: 11905767 DOI: 10.1016/s1470-2045(00)00292-8] [Citation(s) in RCA: 161] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Various active anticancer agents are derived from plants and terrestrial microorganisms. The isolation of C-nucleosides from the Caribbean sponge, Cryptotheca crypta, four decades ago, provided the basis for the synthesis of cytarabine, the first marine-derived anticancer agent to be developed for clinical use. Cytarabine is currently used in the routine treatment of patients with leukaemia and lymphoma. Gemcitabine, one of its fluorinated derivatives, has also been approved for use in patients with pancreatic, breast, bladder, and non-small-cell lung cancer. Over the past decade, several new experimental anticancer agents derived from marine sources have entered preclinical and clinical trials. This field has expanded significantly as a result of improvements in the technology of deep-sea collection, extraction, and large-scale production through aquaculture and synthesis. In this paper, examples of marine-derived experimental agents that are currently undergoing preclinical and early clinical evaluation are briefly discussed. A summary of the available information on the results of phase I and II trials of agents such as aplidine, ecteinascidin-734 (ET-734), dolastatin 10 and bryostatin 1 is also presented.
Collapse
Affiliation(s)
- G Schwartsmann
- South-American Office for Anticancer Drug Development, Comprehensive Cancer Center, The Lutheran University, Brazil.
| | | | | | | |
Collapse
|
4
|
Bonire JJ, Fricker SP. The in vitro antitumour profile of some 1,2-diaminocyclohexane organotin complexes. J Inorg Biochem 2001; 83:217-21. [PMID: 11237262 DOI: 10.1016/s0162-0134(00)00192-6] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Platinum compounds containing the ligand 1,2-diaminocyclohexane (DACH) such as tetraplatin [PtCl4(DACH)] have been found to be active in cisplatin-resistant tumour models. In an attempt to develop novel metal-based drugs with a different therapeutic profile to cisplatin, we have synthesised a series of tin compounds containing the DACH ligand, including the Sn analogue of tetraplatin [SnCl4(DACH)], and the di- and monoorganotin complexes [Ph2Sn(OAc)2(DACH)], [Bu2Sn(OAc)2(DACH)], [PhSnCl3(DACH)], [BuSn(OAc)3(DACH)], [BuSnCl3(DACH)], and [PhSn(OCOCF3)3(DACH)]. Mossbauer and IR spectroscopy indicates that the Sn(DACH) complexes are hexacoordinated with a molecular structure similar to that of tetraplatin. These compounds were tested for potential antitumour activity against a panel of human tumour cell lines, (SW620, SW1116 colon carcinoma, ZR-75-1 breast carcinoma, HT1376 bladder carcinoma, SKOV-3, PA-1 ovarian carcinoma). [Ph2Sn(penicillinate)], [Ph2Sn(OCOCH2NCOCH2NH2)], [Ph2Sn(OAc)2] were included for comparison. The results show that whereas [SnCl4(DACH)] and the monoorganotin complexes had limited or no activity, the diorganotin DACH complexes were cytotoxic with an associated increase in potency on going from diphenyl to dibutyltin, with mean IC50 values of 7.26+/-4.09 micromol ml(-1) for [Ph2Sn(OAc)2(DACH)] and 2.58+/-0.83 micromol ml(-1) for [Bu2Sn(OAc)2(DACH)] across the cell line panel. Comparison with [Ph2Sn(OAc)2] (IC50 0.69-0.43 micromol ml(-1)) indicated that addition of the DACH ligand resulted in a decrease in cytotoxicity but increased differential toxicity across the cell line panel. These results indicate that the diorganotin DACH complexes merit further investigation as potential metal-based antitumour drugs.
Collapse
Affiliation(s)
- J J Bonire
- Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria
| | | |
Collapse
|
5
|
Kamuhabwa A, Nshimo C, de Witte P. Cytotoxicity of some medicinal plant extracts used in Tanzanian traditional medicine. JOURNAL OF ETHNOPHARMACOLOGY 2000; 70:143-149. [PMID: 10771204 DOI: 10.1016/s0378-8741(99)00161-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Using the ethnomedical data approach, some Tanzanian plants that are used in Tanzanian traditional medicine for cancer or non-cancer diseases were collected and evaluated for cytotoxic activity. The antiproliferative effect of the methanolic extracts (10 and 100 microg/ml) of 47 plants was evaluated in vitro on three human cell lines (HeLa, cervical carcinoma; HT29, colon adenocarcinoma; and A431, skin carcinoma). From the nine plants that are used to treat cancer, two plants (22%) exhibited pronounced cytotoxic effect (<25% cell proliferation) at least in one of the tested cell lines. For the 38 plants that are used to treat non-cancer diseases, 14 plants (37%) exhibited pronounced cytotoxic effect (<25% cell proliferation). Cell type cytotoxic specificity was observed in some extracts. Overall, the A431 cells were much more sensitive to most of the extracts than the other cell lines. For the plants that are used as anticancer herbal drugs, our results indicate that there is no correlation between the reported use of these plants and their cytotoxic activity obtained in this study. However, plants that have shown pronounced cytotoxic activity will be evaluated further for the possible isolation of active antitumor compounds.
Collapse
Affiliation(s)
- A Kamuhabwa
- Laboratorium voor Farmaceutische Biologie en Fytofarmacologie, Faculteit Farmaceutische Wetenschappen, Katholieke Universiteit Leuven, Belgium
| | | | | |
Collapse
|
6
|
Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber WM, Schaper M, Bertram B, Wiessler M, Koepsell H. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci U S A 1998; 95:2914-9. [PMID: 9501190 PMCID: PMC19669 DOI: 10.1073/pnas.95.6.2914] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
For beta-D-glucosylisophosphoramide mustard (beta-D-Glc-IPM), a new alkylating drug in which isophosphoramide mustard is stabilized, a higher selectivity and lower myelotoxicity was observed than for the currently used cytostatic ifosfamide. Because beta-D-Glc-IPM is hydrophilic and does not diffuse passively through the lipid bilayer, we investigated whether a transporter may be involved in the cellular uptake. A variety of cloned Na+-sugar cotransporters were expressed in Xenopus oocytes, and uptake measurements were performed. By tracer uptake and electrical measurements it was found that beta-D-Glc-IPM was transported by the low-affinity Na+-D-glucose cotransporter SAAT1, which had been cloned from pig and is also expressed in humans. At membrane potentials between -50 and -150 mV, a 10-fold higher substrate affinity (Km approximately 0.25 mM) and a 10-fold lower Vmax value were estimated for beta-D-Glc-IPM transport than for the transport of D-glucose or methyl-alpha-D-glucopyranoside (AMG). Transport of beta-D-Glc-IPM and glucose by SAAT1 is apparently performed by the same mechanism because similar sodium dependence, dependence on membrane potential, electrogenicity, and phlorizin inhibition were determined for beta-D-Glc-IPM, D-glucose, and AMG. Transcription of human SAAT1 was demonstrated in various human carcinomas and tumor cell lines. In one of these, the human carcinoma cell line T84, phlorizin inhibitable uptake of beta-D-Glc-IPM was demonstrated with substrate saturation and an apparent Km of 0.4 mM. The data suggest that the Na+-D-glucose cotransporter SAAT1 transports beta-D-Glc-IPM into human tumor cells and may accumulate the drug in the cells. They provide an example for drug targeting by employing a plasma membrane transporter.
Collapse
Affiliation(s)
- M Veyhl
- Institute of Anatomy of the Bayerische Julius-Maximilians-Universität, Koellikerstr. 6, 97070 Würzburg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Buckley RG, Elsome AM, Fricker SP, Henderson GR, Theobald BR, Parish RV, Howe BP, Kelland LR. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. J Med Chem 1996; 39:5208-14. [PMID: 8978849 DOI: 10.1021/jm9601563] [Citation(s) in RCA: 148] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Four analogues of the gold(III) complex [AuCl2(damp)] (1) (damp = 2-[(dimethylamino)methyl]phenyl) have been evaluated for antitumor activity. The compounds have structural features in common with cisplatin which was included as a comparison in the study. In vitro, against a panel of cell lines established from tumors of different tissue types, the gold complexes showed broadly similar growth inhibitory properties with some selectivity to the HT1376 bladder cell line. In a panel of human ovarian carcinoma cell lines, non-cross-resistance to cisplatin was observed, for the complexes, in an acquired cisplatin-resistant line. In vivo, using subcutaneously implanted xenografts derived from the HT1376 bladder and CH1 ovarian cell lines, [Au(acetato)2(damp)] (3) and [Au(malonato)(damp)] (5) (administered intraperitoneally) gave significant tumor inhibition. Mechanistic studies performed with compound 3 showed marked differences to cisplatin. Thus, much higher concentrations of the gold compound were required to affect Col E1 plasmid mobility, and an alkaline elution study showed that 3 did not cause interstrand DNA cross-links in SK-OV-3 cells. Exposure of SK-OV-3 cells to 3 induced only relatively minor changes in cell cycle distribution. Furthermore 3 was only marginally active in vivo against the cisplatin-sensitive murine ADJ/PC6 plasmacytoma. In summary, the gold-(III) complexes 3 and 5 exhibited selective cytotoxicity in vitro and showed in vivo antitumor activity against human carcinoma xenografts. Also, although 3 has some structural similarity to cisplatin, its mode of action appears to be different.
Collapse
Affiliation(s)
- R G Buckley
- Biomedical Department, Johnson Matthey Technology Centre, Sonning Common, Reading, Berkshire, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
8
|
|
9
|
Workman P, D'Incalci M, Bursch W, Harrap KR, Hawkins RE, Neidle S, Powis G. European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2). Eur J Cancer 1994; 30A:1148-60. [PMID: 7654448 DOI: 10.1016/0959-8049(94)90475-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- P Workman
- CRC Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, U.K
| | | | | | | | | | | | | |
Collapse
|